Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
5.17
+0.04 (0.78%)
At close: Feb 21, 2025, 4:00 PM
5.18
+0.01 (0.19%)
After-hours: Feb 21, 2025, 6:03 PM EST
Alumis Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
281.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALMS News
- 12 days ago - Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 12 days ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 15 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. - PRNewsWire
- 16 days ago - Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - GlobeNewsWire
- 25 days ago - Alumis Strengthens Leadership Team with Key Appointments - GlobeNewsWire
- 3 months ago - Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 4 months ago - Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - Benzinga
- 5 months ago - Alumis: Could This Broken Immunology IPO Become The Next Amgen? - Seeking Alpha